Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2003 2
2005 1
2009 3
2010 7
2011 3
2012 4
2013 4
2014 2
2015 3
2016 3
2017 3
2018 6
2019 2
2020 5
2021 7
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Results by year

Filters applied: . Clear all
Page 1
Interferon-ε is a tumour suppressor and restricts ovarian cancer.
Marks ZRC, Campbell NK, Mangan NE, Vandenberg CJ, Gearing LJ, Matthews AY, Gould JA, Tate MD, Wray-McCann G, Ying L, Rosli S, Brockwell N, Parker BS, Lim SS, Bilandzic M, Christie EL, Stephens AN, de Geus E, Wakefield MJ, Ho GY, McNally O; Australian Ovarian Cancer Study; McNeish IA, Bowtell DDL, de Weerd NA, Scott CL, Bourke NM, Hertzog PJ. Marks ZRC, et al. Among authors: stephens an. Nature. 2023 Aug;620(7976):1063-1070. doi: 10.1038/s41586-023-06421-w. Epub 2023 Aug 16. Nature. 2023. PMID: 37587335
Role of the prorenin receptor in endometrial cancer cell growth.
Martin JH, Mohammed R, Delforce SJ, Skerrett-Byrne DA, de Meaultsart CC, Almazi JG, Stephens AN, Verrills NM, Dimitriadis E, Wang Y, Lumbers ER, Pringle KG. Martin JH, et al. Among authors: stephens an. Oncotarget. 2022 Apr 1;13:587-599. doi: 10.18632/oncotarget.28224. eCollection 2022. Oncotarget. 2022. PMID: 35401936 Free PMC article.
TRACEBACK: Testing of Historical Tubo-Ovarian Cancer Patients for Hereditary Risk Genes as a Cancer Prevention Strategy in Family Members.
Delahunty R, Nguyen L, Craig S, Creighton B, Ariyaratne D, Garsed DW, Christie E, Fereday S, Andrews L, Lewis A, Limb S, Pandey A, Hendley J, Traficante N, Carvajal N, Spurdle AB, Thompson B, Parsons MT, Beshay V, Volcheck M, Semple T, Lupat R, Doig K, Yu J, Chen XQ, Marsh A, Love C, Bilic S, Beilin M, Nichols CB, Greer C, Lee YC, Gerty S, Gill L, Newton E, Howard J, Williams R, Norris C, Stephens AN, Tutty E, Smyth C, O'Connell S, Jobling T, Stewart CJR, Tan A, Fox SB, Pachter N, Li J, Ellul J, Mir Arnau G, Young MA, Gordon L, Forrest L, Harris M, Livingstone K, Hill J, Chenevix-Trench G, Cohen PA, Webb PM, Friedlander M, James P, Bowtell D, Alsop K; Australian Ovarian Cancer Study, Ovarian Cancer Prognosis and Lifestyle Study and the TRACEBACK Study. Delahunty R, et al. Among authors: stephens an. J Clin Oncol. 2022 Jun 20;40(18):2036-2047. doi: 10.1200/JCO.21.02108. Epub 2022 Mar 9. J Clin Oncol. 2022. PMID: 35263119 Free PMC article.
Chemoresistance is mediated by ovarian cancer leader cells in vitro.
Karimnia N, Wilson AL, Green E, Matthews A, Jobling TW, Plebanski M, Bilandzic M, Stephens AN. Karimnia N, et al. Among authors: stephens an. J Exp Clin Cancer Res. 2021 Sep 1;40(1):276. doi: 10.1186/s13046-021-02086-3. J Exp Clin Cancer Res. 2021. PMID: 34470672 Free PMC article.
Active Ratio Test (ART) as a Novel Diagnostic for Ovarian Cancer.
Kang SW, Rainczuk A, Oehler MK, Jobling TW, Plebanski M, Stephens AN. Kang SW, et al. Among authors: stephens an. Diagnostics (Basel). 2021 Jun 7;11(6):1048. doi: 10.3390/diagnostics11061048. Diagnostics (Basel). 2021. PMID: 34200333 Free PMC article.
57 results